

Cannabis Technologies Inc. to List on CSE, Delist from TSX

May 20, 2014 (Source: Marketwired) – **Cannabis Technologies Inc. (CSE:CAN)** (previously Meridex Software) is pleased to announce that it has received final approval to list its common shares on the Canadian Securities Exchange (the “CSE”), and has voluntarily delisted its common shares from the TSX Venture Exchange. The company will begin trading on the CSE at market open on May 21, 2014. The Company’s trading symbol will be “CAN”.

About Cannabis Technologies Inc.

Cannabis Technologies Inc. is a biopharmaceutical company that specializes in developing cannabis-based botanical and non-botanical therapies through the Research and Development into the extensive pharmacology of cannabinoids.

The company will utilize its proprietary “**Cannabinoid Drug Design Platform**” to identify new bioactive compounds within the marijuana plant that can treat specific diseases and the genes responsible for those diseases.

Our extensive research and new intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Glaucoma, Cancer & Angiogenesis, inflammation, pain & arthritis. Please visit our website at: www.cannabis-tech.com

ON BEHALF OF THE BOARD

Craig Schneider, President and CEO

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements

should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause Meridex Software's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and Meridex Software disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.